Skip to content

MB Therapeutics
A company dedicated to serving patients

Innovation for personalized treatments


Because we believe that one size doesn’t fit all, MB Therapeutics was born.

MB Therapeutics brings together over 8 years of experience conducted at the Faculty of Pharmacy of the University of Montpellier and the University Hospital Center of Nîmes. 

These research efforts led to a collaboration with Lynxter, a company based in Bayonne specialized in the development, Sanofi and production of industrial 3D printers.

In 2022, MB Therapeutics was established to provide a comprehensive solution for the manufacture of personalized and innovative medications for healthcare professionals.

Stéphane Roulon, Lynxter and Ian Soulairol, a team expert in pediatric 3D printing domain

Pionniering a new era of healthcare, MB Therapeutics mission

Medicines, New Gen


Making each medication unique through a comprehensive ecosystem, from pharmaceutical formulation to 3D printing technology.

Turnkey personalized medicine


We are developing a comprehensive solution from pharmaceutical raw materials to 3D printers, providing healthcare professionals with a turnkey solution.


Medications. Everywhere. For everyone.

In countries where the supply chain can be complex or where access to medicine is limited, the MB solution helps improve the access of populations to treatments.

 Different medications for each individual.

 Each patient is different. The MB solution puts the patient at the center, allowing for the adaptation of medication dosage and form based on individual patients.

 Excipients that are finally respectful to our children.

MB formulation is a safe composition for our children, with no excipients that have known effects or contraindications for certain age groups.